Celyad Oncology SA
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding … Read more
Celyad Oncology SA (CLYYF) - Total Liabilities
Latest total liabilities as of June 2025: $8.80 Million USD
Based on the latest financial reports, Celyad Oncology SA (CLYYF) has total liabilities worth $8.80 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Celyad Oncology SA - Total Liabilities Trend (2010–2024)
This chart illustrates how Celyad Oncology SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Celyad Oncology SA Competitors by Total Liabilities
The table below lists competitors of Celyad Oncology SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Banzai International Inc
NASDAQ:BNZI
|
USA | $27.55 Million |
|
Charlie's Holdings Inc.
OTCQB:CHUC
|
USA | $7.32 Million |
|
Magna Prima Bhd
KLSE:7617
|
Malaysia | RM31.69 Million |
|
PT Jobubu Jarum Minahasa Tbk
JK:BEER
|
Indonesia | Rp19.70 Billion |
|
PT UBC Medical Indonesia Tbk
JK:LABS
|
Indonesia | Rp66.77 Billion |
|
Hapbee Technologies Inc
PINK:HAPBF
|
USA | $3.86 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Celyad Oncology SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celyad Oncology SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celyad Oncology SA (2010–2024)
The table below shows the annual total liabilities of Celyad Oncology SA from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $26.05 Million | +161.05% |
| 2023-12-31 | $9.98 Million | -35.20% |
| 2022-12-31 | $15.40 Million | -57.58% |
| 2021-12-31 | $36.30 Million | +3.46% |
| 2020-12-31 | $35.09 Million | -20.64% |
| 2019-12-31 | $44.22 Million | +14.23% |
| 2018-12-31 | $38.71 Million | +28.64% |
| 2017-12-31 | $30.09 Million | -37.21% |
| 2016-12-31 | $47.92 Million | -0.27% |
| 2015-12-31 | $48.05 Million | +177.89% |
| 2014-12-31 | $17.29 Million | +11.65% |
| 2013-12-31 | $15.49 Million | +2.85% |
| 2012-12-31 | $15.06 Million | +149.42% |
| 2011-12-31 | $6.04 Million | -31.43% |
| 2010-12-31 | $8.80 Million | -- |